Goldman Sachs Comments on Gilead Sciences

Goldman Sachs provided color on Gilead Sciences GILD in a research report published today. Goldman Sachs has a Buy rating on Gilead Sciences. In the report, Goldman Sachs states, "GILD licensed the rights to Boehringer Ingelheim's (BI) non-catalytic site integrase inhibitors (NCINIs) for the treatment of HIV, including the lead compound BI-224436 in Phase I. NCINI's have the potential to be a novel class of HIV drugs that target the HIV integrase (responsible for integrating the viral DNA into the host) in a different way than existing integrase inhibitors (Isentress and elvitegravir)." Shares of Gilead Sciences were trading at $39.10 at the time of posting, down 0.13% from Wednesday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsGoldman Sachs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!